$ Value
$37K
Shares
7,666
Price
$5
Filed
Oct 7
Insider
Name
Jorgensen Nathan D.
Title
Chief Financial Officer
CIK
0001842523
Roles
Transaction Details
Transaction Date
2025-10-03
Code
S
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
123,834
Footnotes
Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter adopted by the reporting person on May 9, 2025 effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on October 3, 2025. The sales do not represent a discretionary trade by the reporting person. | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.74 to $4.85, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
Filing Info
Jorgensen Nathan D.'s History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-02-24 | VYGR | ▼ | $18K |
| 2026-02-06 | VYGR | A | $0 |
| 2026-02-06 | VYGR | A | $0 |
| 2025-10-03 | VYGR | ▼ | $37K |
Other Insiders at VYGR (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
Sandrock Alfred
President and CEO
|
— | $184K | 2026-04-02 |
|
Jorgensen Nathan D.
Chief Financial Officer
|
— | $18K | 2026-02-24 |
|
Swartz Robin
COO & CBO
|
— | $55K | 2026-02-24 |
|
Carter Todd Alfred
Chief Scientific Officer
|
— | $41K | 2026-02-24 |
|
Ferguson Toby
Chief Medical Officer
|
— | — | 2026-02-06 |
|
Shiferman Gregory L.
SVP and General Counsel
|
— | — | 2026-04-01 |